Outpatient Treatment of Confirmed COVID-19 (Version 2)
Publication Date: September 19, 2023
Practice Points
Consider molnupiravir to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease.
6731
Consider nirmatrelvir–ritonavir combination therapy to treat symptomatic patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 5 days of the onset of symptoms and at a high risk for progressing to severe disease.
6731
Practice Point 3: Consider remdesivir to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting who are within 7 days of the onset of symptoms and at high risk for progressing to severe disease.
6731
Practice Point 4: Do not use azithromycin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 5: Do not use chloroquine or hydroxychloroquine to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 6: Do not use ivermectin to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 7: Do not use nitazoxanide to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 8: Do not use lopinavir–ritonavir combination therapy to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 9: Do not use casirivimab–imdevimab combination therapy to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting unless it is considered effective against a SARS-CoV-2 variant or subvariant locally in circulation.
6731
Practice Point 10: Do not use regdanvimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting unless it is considered effective against a SARS-CoV-2 variant or subvariant locally in circulation.
6731
Practice Point 11: Do not use sotrovimab to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 12: Do not use convalescent plasma to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 13: Do not use ciclesonide to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Practice Point 14: Do not use fluvoxamine to treat patients with confirmed mild to moderate COVID-19 in the outpatient setting.
6731
Title
Outpatient Treatment of Confirmed COVID-19
Authoring Organization
American College of Physicians
Publication Month/Year
September 19, 2023
Country of Publication
US
Document Objectives
The SMPC developed version 1 of these living, rapid practice points to summarize the best available evidence about the use of pharmacologic and biologic treatments of COVID-19 in the outpatient setting. These practice points do not address the use of COVID-19 treatments in the inpatient setting or adjunctive treatments of COVID-19 in the outpatient setting. Table 1 and Figures 1 and 2 summarize the current evidence.
Inclusion Criteria
Male, Female, Adolescent, Older adult
Health Care Settings
Ambulatory, Outpatient
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D000086382 - COVID-19, D000086402 - SARS-CoV-2
Keywords
outpatient, Coronavirus, covid-19, COVID, SARS-CoV-2
Source Citation
Sommer I, Ledinger D, Thaler K, Dobrescu A, Persad E, Fangmeyer M, Klerings I, Gartlehner G. Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2). Ann Intern Med. 2023 Sep 19. doi: 10.7326/M23-1626. Epub ahead of print. PMID: 37722115.
Qaseem A, Yost J, Miller MC, Andrews R, Jokela JA, Forciea MA, Abraham GM, Humphrey LL; Scientific Medical Policy Committee of the American College of Physicians. Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1). Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2249. Epub ahead of print. PMID: 36442061.